- Home
- PIRS vs PTN Comparison
PIRS vs PTN Comparison
Compare PIRS & PTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIRS
- PTN
- Stock Information
- Founded
- PIRS 2001
- PTN 1986
- Country
- PIRS United States
- PTN United States
- Employees
- PIRS N/A
- PTN N/A
- Industry
- PIRS Biotechnology: Pharmaceutical Preparations
- PTN Biotechnology: Pharmaceutical Preparations
- Sector
- PIRS Health Care
- PTN Health Care
- Exchange
- PIRS Nasdaq
- PTN Nasdaq
- Market Cap
- PIRS 22.4M
- PTN 25.4M
- IPO Year
- PIRS N/A
- PTN 1993
- Fundamental
- Price
- PIRS $15.93
- PTN $0.92
- Analyst Decision
- PIRS
- PTN Strong Buy
- Analyst Count
- PIRS 0
- PTN 1
- Target Price
- PIRS N/A
- PTN $17.00
- AVG Volume (30 Days)
- PIRS 37.6K
- PTN 267.1K
- Earning Date
- PIRS 11-13-2024
- PTN 11-14-2024
- Dividend Yield
- PIRS N/A
- PTN N/A
- EPS Growth
- PIRS N/A
- PTN N/A
- EPS
- PIRS N/A
- PTN N/A
- Revenue
- PIRS $1,352,000.00
- PTN $2,384,113.00
- Revenue This Year
- PIRS N/A
- PTN N/A
- Revenue Next Year
- PIRS N/A
- PTN N/A
- P/E Ratio
- PIRS N/A
- PTN N/A
- Revenue Growth
- PIRS N/A
- PTN N/A
- 52 Week Low
- PIRS $6.20
- PTN $0.68
- 52 Week High
- PIRS $22.32
- PTN $5.65
- Technical
- Relative Strength Index (RSI)
- PIRS 43.29
- PTN 38.12
- Support Level
- PIRS $15.15
- PTN $0.90
- Resistance Level
- PIRS $16.97
- PTN $1.26
- Average True Range (ATR)
- PIRS 0.72
- PTN 0.11
- MACD
- PIRS -0.08
- PTN -0.03
- Stochastic Oscillator
- PIRS 30.75
- PTN 4.00
About PIRS Pieris Pharmaceuticals Inc.
Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store, and transport a wide spectrum of molecules. The Company's clinical pipeline consists of immuno-oncology, or IO, bispecifics in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Geographically, all the operations of the firm function through the region of the United States.
About PTN Palatin Technologies Inc.
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.